Orion Oyj
31.3.2026 17:00:00 CEST | Globenewswire | Press release
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
31 March 2026 at 18:00 EEST
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds, and the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 30 March 2026 above five (5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to notification:
| % of shares and voting rights (total of point A) | % of shares and voting rights through financial instruments (total of point B) | Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 5.11% shares Below 5% voting rights | 0.00% shares Below 5% voting rights | 5.11% shares Below 5% voting rights | 141,134,278 shares 740,104,338 voting rights |
| Position of previous notification (if applicable) | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights | Below 5% shares Below 5% voting rights |
Notified details of the resulting situation on the date on which the threshold was crossed:
Point A: Shares and voting rights:
| Class/type of shares ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009014377 | 7,212,746 shares Below 5% voting rights | 5.11% shares Below 5% voting rights | ||
| POINT A SUBTOTAL | 7,212,746 shares Below 5% voting rights | 5.11% shares Below 5% voting rights | ||
Point B: Financial instruments according to SMA 9:6a:
| Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| American Depositary Receipt (US68628Y1047) | N/A | N/A | Physical | 200 shares Below 5% voting rights | 0.00% shares Below 5% voting rights |
| CFD | N/A | N/A | Cash | 2,719 shares Below 5% voting rights | 0.00% shares Below 5% voting rights |
| POINT B SUBTOTAL | 2,919 shares Below 5% voting rights | 0.00% shares Below 5% voting rights |
Orion Corporation
| Liisa Hurme President and CEO | Mikko Kemppainen General Counsel |
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orionpharma.com
Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Pineal Capital Management31.3.2026 20:13:25 CEST | Press release
Pineal Capital Management Issues Open Letter to the Board of Teladoc Health, Inc.
Ilkka Oyj31.3.2026 18:00:00 CEST | Press release
Ilkka Oyj: Acquisition of own shares on 31 March 2026
Iveco Group N.V.31.3.2026 18:00:00 CEST | Press release
Iveco Group publishes the Informative Document concerning the sale of its Defence business
BioPorto A/S31.3.2026 17:43:41 CEST | Press release
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
BioPorto A/S31.3.2026 17:43:41 CEST | Pressemeddelelse
BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom